Showing results (1041-1050 of 1,056) with videos related to
Sort By:
Pageof 106
The Lancet. Gastroenterology & Hepatology|September 23, 2021
Fully automated magnetically controlled capsule endoscopy for examination of the stomach and small bowel: a prospective, feasibility, two-centre studyYu-Feng Xiao, Zhi-Xuan Wu, Song He, et al.Cell Reports|July 13, 2022
Inhibition of SIRT2 promotes APP acetylation and ameliorates cognitive impairment in APP/PS1 transgenic miceNing Bai, Na Li, Rong Cheng, et al.Science Advances|December 17, 2021
Comprehensive analysis of spatial architecture in primary liver cancerRui Wu, Wenbo Guo, Xinyao Qiu, et al.Acta Tropica|November 10, 2025
Epizootiology and mitochondrial genetic diversity of Taenia hydatigena in Nigerian small ruminants: Implications for one health controlTharheer Oluwashola Amuda, Olajumoke Abimbola Morenikeji, Li Li, et al.Lancet (London, England)|August 28, 2016
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialLi Zhang, Yan Huang, Shaodong Hong, et al.Science Advances|July 20, 2022
Progerin modulates the IGF-1R/Akt signaling involved in agingBo Jiang, Xuan Wu, Fang Meng, et al.Nature Communications|July 18, 2019
The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinomaShaodong Hong, Dongbing Liu, Shuzhen Luo, et al.Nature Genetics|January 17, 2012
Whole-genome sequence of Schistosoma haematobiumNeil D Young, Aaron R Jex, Bo Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2021
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III StudyShaodong Hong, Yaxiong Zhang, Gengsheng Yu, et al.Phenomics (Cham, Switzerland)|March 10, 2025
Cohort Profile: TRacing Etiology of Non-communicable Diseases (TREND): Rationale, Progress and PerspectiveHui-Ying Ren, Ying Lv, Bei-Ning Ma, et al.Pageof 106